CDKN2A and central nervous system cancer: Similarly, the frequency at which homozygous CDKN2A loss was detected in our cohort at each grade (grade 2: 1.8%, grade 3: 3.2%, grade 4: 27%) is similar to the proportion of IHDm astrocytomas in The Cancer Genome Atlas (TCGA) combined low grade glioma and glioblastoma cohorts (grade 2: 3.5%, grade 3: 6.7%, grade 4: 18.8%; primary tumors, multiple methods of CDKN2A assessment) [8].